LOW FLAT RATE AUST-WIDE $9.90 DELIVERY INFO

Close Notification

Your cart does not contain any items

Pathophysiology and Treatment of Atherosclerotic Disease in Peripheral Arteries

Aloke Virmani Finn, MD (Director and Chief Scientific Officer, CVPath)

$290.95

Paperback

Not in-store but you can order this
How long will it take?

QTY:

English
Elsevier - Health Sciences Division
14 June 2024
Pathophysiology and Treatment of Atherosclerotic Disease in Peripheral Arteries is a thorough review of the disease written by experts studying its detection and treatment. These state-of-the-art chapters summarize emerging knowledge about this important area of medicine. The pathophysiology and treatment of peripheral artery (PAD) disease remains poorly understood even by practitioners. Often it is assumed that PAD should be treated in a similar fashion to coronary artery disease (CAD), when in fact recent data suggest a distinct pathophysiology with genetic risk having some but not complete overlap with CAD.

This is a novel reference of emerging data on the factors behind its development and progression, detection, and treatment suggest an emerging paradigm for this disease.
Edited by:  
Imprint:   Elsevier - Health Sciences Division
Country of Publication:   United States
Dimensions:   Height: 235mm,  Width: 191mm, 
Weight:   450g
ISBN:   9780443135934
ISBN 10:   0443135932
Pages:   252
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Paperback
Publisher's Status:   Active
1. Introduction 2. Atherosclerosis- pathology of lower extremity atherosclerosis 3. Epidemiology of PAD 4. Molecular Understanding of Peripheral Arterial Disease 5. Non-invasive imaging of CT and MRA in Evaluation of PAD 6. Medical Therapy of PAD: Joshua Beckman 7. Intravascular Imaging: Role in PAD 8. Interventional Treatment of PAD: Atherectomy 9. Interventional Treatment of PAD: Drug Coated Balloons and Stents 10. Future Directions

Dr. Aloke Virmani Finn is a physician-scientist whose focus is on the pathology of cardiovascular disease and its treatment.?He serves as the Medical Director and Chief Scientific Officer for CVPath Institute where he oversees device development research and runs a molecular lab with focus on the molecular understanding of vascular wall injury and healing, genetics of sudden cardiac death and molecular basis of coronary artery disease.? When not running CVPath, he performs interventional cardiology procedures at University of Maryland.

See Also